Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 719 of 5804
-
Heart pump could outperform drugs in advanced heart failure
Disease control Recruiting nowHeart failure is a severe disease affecting approximately 1-2% of the adult population in developed countries and around 26 million people worldwide. Up to 10% of these patients are in advanced stage heart failure, which is defined by a significant morbimortality and considerable…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Sanofi's new COVID vaccine shows promise in large trial
⭐️ VACCINE ⭐️ CompletedThe primary objectives of the study are: To assess the safety profile of the study vaccines in each study intervention group. To assess the neutralizing antibody profile after primary series vaccination in SARS-CoV-2-naïve adults. To demonstrate that a booster dose of monovale…
Phase: PHASE2, PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 18:35 UTC
-
New cell therapy takes on advanced kidney cancer
Disease control OngoingThis is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental cell therapy takes on Hard-to-Treat myeloma
Disease control CompletedThe purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Phase: PHASE1 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Promising drug combo slows advanced prostate cancer in major trial
Disease control CompletedThe purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to stop small liver cancers from coming back
Disease control OngoingFollowing the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a promising treatment option for patients with HCC. In addition, the high intrahepatic distant recurrence rate and accumulating evidence for a metastatic mechanism encourages exploring adjuv…
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingA Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to slow prostate cancer spread
Disease control Recruiting nowBackground: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel with androgen deprivation therapy can improve survival for men with mCSPC. Researche…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare kidney cancer
Disease control CompletedThis study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Poop pills plus immunotherapy: new hope for colorectal cancer patients?
Disease control OngoingThis phase II trial studies the effect of fecal microbiota transplant and re-introduction of anti-PD-1 therapy (pembrolizumab or nivolumab) in treating anti-PD-1 non-responders with colorectal cancer that has spread to other places in the body (metastatic). Fecal microbiota trans…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for Hard-to-Treat myeloma: teclistamab trial in japan
Disease control CompletedThe purpose of the study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001 (NCT03145181) in Phase 1 part and to evaluate the efficacy o…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New trial aims to tame transplant complications in blood cancer patients
Disease control Recruiting nowA multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
Phase: PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
AI-Powered MRI could eliminate need for brain tumor biopsies
Diagnosis Recruiting nowGlioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help …
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New drug combo offers hope for older AML patients who Can't tolerate chemo
Disease control OngoingThis phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or elderly patients with newly diagnosed acute myeloid leukemia who are not ca…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to stall pancreatic cancer in BRCA patients
Disease control OngoingThis phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 ar…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo treatment aims to tackle deadly brain tumors
Disease control Recruiting nowThe purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas.
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Daily pill shows promise for Long-Term migraine prevention
Prevention CompletedThis study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
Phase: PHASE3 • Sponsor: AbbVie • Aim: Prevention
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktail aims to outsmart tough blood cancer
Disease control Recruiting nowThe purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of romidepsin and oral azacytidin…
Phase: PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New Pump-Delivered Parkinson's drug shows promise in Long-Term safety trial
Disease control CompletedParkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effe…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Acupuncture vs. sham needles: a test for chemo nerve damage
Symptom relief CompletedThe purpose of this study is to assess the neurological efficacy of acupuncture in patients with cancer who experienced peripheral neuropathy, which is induced by chemotherapy.
Phase: NA • Sponsor: China Medical University Hospital • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC